HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC Drops Hammer On Skin Care Sellers For Deceptive 'Risk Free' Trials

This article was originally published in The Tan Sheet

Executive Summary

A federal court issues a temporary restraining order in response to FTC's complaint citing seven individuals and a "maze of interrelated shell companies" for deceptive "risk-free" skin-care trial offers. Buried in fine print on the companies' websites were terms specifying charges for unsuspecting consumers, FTC says.

You may also be interested in...

'Free Trial' Offers Cost Marketers Of Supplements With Bogus Claims

FTC sends refunds totaling $60,791 to purchasers of Nobetes' product touted as diabetes treatment and $113,000 for purchases of FlexiPrin, a deceptively marketed joint pain supplement. Commission previously settled with both firms.

FTC Prioritizes Health Claims, Disclosures Enforcement In Coming Year

In a presentation at the National Advertising Division Annual Conference, FTC Chairwoman Edith Ramirez discussed the commission’s priorities for the year ahead. Health claims and inadequate disclosures top the list following related settlements with advertisers in 2013 and the agency’s Operation Full Disclosure initiative.

FTC: All Advertisers Should Heed Lessons From “Operation Full Disclosure”

On the heels of FTC’s “Operation Full Disclosure,” which resulted in 60 warning letters, commission officials advise all advertisers to pay close attention to their disclosures and ensure they are clear and conspicuous. The initiative included review of 1,000 national television and print ads, and the agency says it will continue to monitor the advertising landscape for inadequate disclosure use.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts